These are the most popular stories from the Wall Street Journal. These stories have not been verified and we cannot vouch their accuracy. U.S.

Cassava and former executives were charged Thursday by the SEC with making misleading claims in 2020 about trials for the ...

The Securities and Exchange Commission alleged that a researcher for the company manipulated trial data to make its drug ...

Relatedly, the SEC also charged Hoau-Yan Wang, a Cassava consultant and an associate professor at the City University of New York's Medical School, for manipulating the reported clinical trial results ...

AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company ...

After a third review of safety data, an independent board recommended two trials of simufilam for Alzheimer's continue ...

Cassava's financial challenges and data integrity concerns remain critical. Learn why SAVA stock is rated a strong sell given ...

Cassava Sciences' stock rose 9% after completing a trial of its Alzheimer's drug, Simufilam, but the company's future remains ...

Cassava Sciences, Inc. (NASDAQ:SAVA) on Tuesday announced the completion of an interim safety review of its Alzheimer's drug ...

Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials.The DSMB Recommended ...

Following our analysis of the options activities associated with Cassava Sciences, we pivot to a closer look at the company's ...

“Our first Phase 3 trial,” he continued, “is expected to read out by year end 2024, with 804 patients randomized 1:1 between simufilam and placebo. Top-line results for the second Phase 3 ...